doxapram has been researched along with Bronchial Neoplasms in 1 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Bronchial Neoplasms: Tumors or cancer of the BRONCHI.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Laxenaire, MC | 1 |
Boileau, S | 1 |
Dagrenat, P | 1 |
Menu, N | 1 |
Drouet, N | 1 |
1 trial available for doxapram and Bronchial Neoplasms
Article | Year |
---|---|
Haemodynamic and respiratory effects of post-operative doxapram and almitrine in patients following pneumonectomy.
Topics: Almitrine; Blood Pressure; Bronchial Neoplasms; Doxapram; Hemodynamics; Humans; Male; Myocardial Con | 1986 |